Rifaximin treatment for individual and multiple symptoms of irritable bowel syndrome with diarrhea: an analysis using new end points

Lacy BE, et al. Clin Ther. 2023

A narrative review of irritable bowel syndrome with diarrhea: a primer for primary care providers

Moshiree B, et al. Advances in Therapy. 2022.

Shortcomings of trials assessing antidepressants in the management of irritable bowel syndrome: a critical review 

Oh SJ, et al. Journal of Clinical Medicine. 2020.

Abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea 

Lembo A, et al. Clinical and Translational Gastroenterology. 2020

Clinical management of the microbiome in irritable bowel syndrome

Andrews CN, et al. Journal of the Canadian Association of Gastroenterology. 2020.

Current US food and drug administration-approved pharmacologic therapies for the treatment of irritable bowel syndrome with diarrhea

Brenner DM, et al. Advances in Therapy. 2020.

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review

Chey WD, et al. Therapeutic Advances in Gastroenterology. 2020.

Lactulose breath testing as a predictor of response to rifaximin in patients with irritable bowel syndrome with diarrhea 

Rezaie A, et al. The American Journal of Gastroenterology. 2019.

Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions 

Cangemi DJ, et al. Therapeutic Advances in Gastroenterology. 2019.

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome

Fodor AA, et al. Gut Microbes. 2019.

Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome

Lacy BE. Alimentary Pharmacology & Therapeutics. 2018.

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin 

Chang C. Clinical and Experimental Gastroenterology. 2018.

Practical evaluation and management of irritable bowel syndrome with diarrhea: a case study approach 

Lacy BE. Journal of Family Practice. 2018.

Diarrhea-predominant irritable bowel syndrome: diagnosis and therapeutic options

Weinstock LB. Consultant. 2018.

Gut microbiota-based therapies for irritable bowel syndrome 

Stern EK, et al. Clinical and Translational Gastroenterology. 2018.

Evidence-based management of irritable bowel syndrome with diarrhea 

Pimentel M. The American Journal of Managed Care. 2018.

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome 

Harris LA, et al. Postgraduate Medicine. 2017.

Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial 

Cash BD, et al. Therapeutic Advances in Gastroenterology. 2017.

Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity 

Pimentel M, et al. Digestive Diseases and Sciences. 2017.

Role of the microbiome in disease: implications for treatment of irritable bowel syndrome 

Lacy BE. Journal of Family Practice. 2017.

Antimicrobial susceptibility of Staphylococcus isolates from the skin of patients with diarrhea-predominant irritable bowel syndrome treated with repeat courses of rifaximin 

DuPont HL, et al. Antimicrobial Agents and Chemotherapy. 2016.

Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome 

Lembo A, et al. Gastroenterology. 2016.

Advances in IBS 2016: a review of current and emerging data 

Schoenfeld PS. Journal of Gastroenterology and Hepatology. 2016.

Diarrhea-predominant irritable bowel syndrome: diagnosis, etiology, and new treatment considerations 

Lacy BE, et al. Journal of the American Association of Nurse Practitioners. 2016.

Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome 

Acosta A, et al. Clinical and Translational Gastroenterology. 2016.

New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists 

Foxx-Orenstein AE. Therapeutic Advances in Gastroenterology. 2016.

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome 

Lacy BE. International Journal of General Medicine. 2016.

Review article: The antimicrobial effects of rifaximin on the gut microbiota 

Dupont HL. Alimentary Pharmacology & Therapeutics [Supplement]. 2016.

Review article: Potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea

Pimentel M. Alimentary Pharmacology & Therapeutics [Supplement]. 2016.

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach 

Soldi S, et al. Clinical and Experimental Gastroenterology. 2015.

Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects 

Pimentel M, et al. PLoS One. 2015.

New and emerging treatment options for irritable bowel syndrome 

Lacy BE, et al. Journal of Gastroenterology and Hepatology. 2015.

Editorial: Safety and tolerability of rifaximin for IBS - more information is required; authors' reply 

Schoenfeld P, et al. Alimentary Pharmacology & Therapeutics. 2014.

Antibiotic treatment of constipation-predominant irritable bowel syndrome 

Pimentel M, et al. Digestive Diseases and Sciences. 2014.

Review article: Evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets 

DuPont HL. Alimentary Pharmacology & Therapeutics. 2014.

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials 

Schoenfeld P, et al. Alimentary Pharmacology & Therapeutics. 2014.

Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review 

Schmulson M, et al. Mexican Journal of Gastroenterology. 2014.

Comment on: Rifaximin in the treatment of irritable bowel syndrome. Is there a high risk for development of antimicrobial resistance?

Calanni F, et al. Journal of Clinical Gastroenterology. 2013.

Postinfectious chronic gut dysfunction: from bench to bedside 

Collins SM, et al. The American Journal of Gastroenterology [Supplement]. 2012.

Manipulation of the gut microbiota as a novel treatment strategy for gastrointestinal disorders 

Foxx-Orenstein AE, et al. The American Journal of Gastroenterology [Supplement]. 2012.

Intestine microbes in gastroenterology: health and disease 

Pimentel M. The American Journal of Gastroenterology [Supplement]. 2012.

Intestinal microbes in inflammatory bowel diseases

Sartor RB, et al. The American Journal of Gastroenterology [Supplement]. 2012.

Cost savings associated with rifaximin for diarrhea-predominant irritable bowel syndrome 

Pimentel M, et al. American Journal of Pharmacy Benefits. 2012.

The treatment of patients with irritable bowel syndrome: review of the latest data from the 2010 DDW meeting 

Pimentel M. Journal of Gastroenterology and Hepatology. 2010.

An evidence-based position statement on the management of irritable bowel syndrome

Brandt LJ, et al. The American Journal of Gastroenterology. 2009.